193 related articles for article (PubMed ID: 27376201)
41. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats.
Kiyono Y; Iida Y; Kawashima H; Ogawa M; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):999-1005. PubMed ID: 12173012
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
43. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
[TBL] [Abstract][Full Text] [Related]
44. Natural and synthetic corticosteroids inhibit uptake 2-mediated transport in CNS neurons.
Hill JE; Makky K; Shrestha L; Hillard CJ; Gasser PJ
Physiol Behav; 2011 Aug; 104(2):306-11. PubMed ID: 21081135
[TBL] [Abstract][Full Text] [Related]
45. The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter.
Vieira LS; Zhang Y; López Quiñones AJ; Hu T; Singh DK; Stevens J; Prasad B; Park JR; Wang J
J Pharmacol Exp Ther; 2023 Dec; 387(3):239-248. PubMed ID: 37541765
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
47. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
Armour A; Cunningham SH; Gaze MN; Wheldon TE; Mairs RJ
Br J Cancer; 1997; 75(4):470-6. PubMed ID: 9052395
[TBL] [Abstract][Full Text] [Related]
48. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells.
Anton M; Wagner B; Haubner R; Bodenstein C; Essien BE; Bönisch H; Schwaiger M; Gansbacher B; Weber WA
J Gene Med; 2004 Jan; 6(1):119-26. PubMed ID: 14716684
[TBL] [Abstract][Full Text] [Related]
49. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells.
Rutgers M; Tytgat GA; Verwijs-Janssen M; Buitenhuis C; Voûte PA; Smets LA
Int J Cancer; 1993 May; 54(2):290-5. PubMed ID: 8486431
[TBL] [Abstract][Full Text] [Related]
50. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
Vaidyanathan G; Affleck DJ; Norman J; O'Dorisio S; Zalutsky MR
Bioconjug Chem; 2007; 18(6):2122-30. PubMed ID: 17979223
[TBL] [Abstract][Full Text] [Related]
51. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
[TBL] [Abstract][Full Text] [Related]
52. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
53. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
54. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
[No Abstract] [Full Text] [Related]
55. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
56. Sympathomimetic effects of MIBG: comparison with tyramine.
Graefe KH; Bossle F; Wölfel R; Burger A; Souladaki M; Bier D; Dutschka K; Farahati J; Bönisch H
J Nucl Med; 1999 Aug; 40(8):1342-51. PubMed ID: 10450687
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine.
Sun S; Wang K; Lei H; Li L; Tu M; Zeng S; Zhou H; Jiang H
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():1-6. PubMed ID: 24246570
[TBL] [Abstract][Full Text] [Related]
58. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.
Zhao Y; Zhong X; Ou X; Cai H; Wu X; Huang R
Front Med; 2017 Mar; 11(1):120-128. PubMed ID: 28213878
[TBL] [Abstract][Full Text] [Related]
59. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
Accorsi R; Morowitz MJ; Charron M; Maris JM
Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
[TBL] [Abstract][Full Text] [Related]
60. Improved outcome of
Corroyer-Dulmont A; Falzone N; Kersemans V; Thompson J; Allen DP; Able S; Kartsonaki C; Malcolm J; Kinchesh P; Hill MA; Vojnovic B; Smart SC; Gaze MN; Vallis KA
Radiother Oncol; 2017 Sep; 124(3):488-495. PubMed ID: 28595752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
